

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER OF PATENTS AND TRADEMARKS P.O. BOX 1450 Alexandria, Virginia 22313-1450 www.ustob.ozv

				17 27 2 2
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/937,112	05/13/2002	John A. Heyman	INVITI1220-1	4705
75	590 05/20/2003			
Lisa A Haile			EXAMINER	
Gray Cary Ware & Freidenrich Suite 1600			WILDER, CYNTHIA B	
4365 Executive Drive San Diego, CA 92121-2189		·	ART UNIT	PAPER NUMBER
<i>3</i> ,			. 1637	
			DATE MAILED: 05/20/2003	9
				1

Please find below and/or attached an Office communication concerning this application or proceeding.



## Office Action Summary

Application No. 09/937,112

Applicant(s)

Examiner

Art Unit

**HEYMAN** et al.

Cynthia B Wilder 1637



	The MAILING DATE of this communication appears	on the cover sheet with the correspondence address			
	for Reply				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.					
	ions of time may be available under the provisions of 37 CFR 1.136 (a). In a graduate of this communication.	no event, however, may a reply be timely filed after SIX (6) MONTHS from the			
- If NO p - Failure - Any re	period for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply a to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the ply received by the Office later than three months after the mailing date of the platent term adjustment. See 37 CFR 1.704(b).	and will expire SIX (6) MONTHS from the mailing date of this communication.  ne application to become ABANDONED (35 U.S.C. § 133).			
Status					
1) 💢	Responsive to communication(s) filed on Jul 23, 20	002			
2a) 🗆	This action is <b>FINAL</b> . 2b) 💢 This action	ion is non-final.			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.					
Disposit	tion of Claims				
4) 💢	Claim(s) <u>1-34</u>	is/are pending in the application.			
		is/are withdrawn from consideration.			
5) 🗆	Claim(s)	is/are allowed.			
6) 🗆	Claim(s)	is/are rejected.			
7) 🗆	Claim(s)	is/are objected to.			
8) 💢	Çlaims <u>1-34</u>	are subject to restriction and/or election requirement.			
	ition Papers				
9) 🗆	The specification is objected to by the Examiner.				
10)	The drawing(s) filed on is/are	a) $\square$ accepted or b) $\square$ objected to by the Examiner.			
	Applicant may not request that any objection to the d	rawing(s) be held in abeyance. See 37 CFR 1.85(a).			
11)	The proposed drawing correction filed on	is: a) $\square$ approved b) $\square$ disapproved by the Examine			
If approved, corrected drawings are required in reply to this Office action.					
12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13)□	Acknowledgement is made of a claim for foreign pr	iority under 35 U.S.C. § 119(a)-(d) or (f).			
a) □ All b) □ Some* c) □ None of:					
1. Certified copies of the priority documents have been received.					
;	2. $\square$ Certified copies of the priority documents hav	e been received in Application No			
	application from the International Burea				
_	ee the attached detailed Office action for a list of the	·			
	14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).				
_	a) In the translation of the foreign language provisional application has been received.				
15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachm					
_	otice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).			
_	otice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)			
3) [ IM	formation Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Other:			

Application/Control Number: 09/937,112 Page 2

Art Unit: 1637

## **DETAILED ACTION**

## Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, Applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-33, drawn to method of making a full-length coding sequence and expression vector.

Group II, claim(s) 34, drawn to a fusion protein.

- 2. The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:
- (A) The invention has no special technical feature that define the contribution over the prior art, or
- (b) Unity of invention between different categories of invention will only be found to exist if specific combinations of inventions are present. Those combination include:
  - 1) A product and a special process of manufacture of said product.
  - 2) A product and a process of use of said product.

Application/Control Number: 09/937,112

Art Unit: 1637

3) A product, a special process of manufacture of said product, and a process of use of said product.

Page 3

- 4) A process and an apparatus specially designed to carry out said process.
- 5) A product, a special process of manufacture of said product and an apparatus specially designed to carry out said process.

The allowed combination do not include multiple products, multiple methods of using said product, multiple methods of making multiple products as claimed inv the instant application: see MPEP 1850. In the instant case, Applicant's claims encompass multiple inventions, polynucleotide, kit, vaccine, polypeptide and multiple methods of using the polypeptide. MPEP states that "if multiple products, processes of manufacture or uses are claimed, the first invention of the category first mentioned in the claims of the application, the first recited invention of each of the other categories related thereto will be considered as the main invention in the claims ", see PCT Article 17(3)(a) and 1.476(c).

In the instant invention the claims not only comprise multiple inventions but the "the claims do not share "a special technical feature" because a method of making a full-length coding sequence as claimed is known and practice in the prior art (Carninci et al. Genomics, November 1996). Additionally fusion proteins and general procedures for making fusion proteins are well known in the art.

Additionally the inventions are distinct, each from the other because of the following reasons:

Application/Control Number: 09/937,112

Page 4

Art Unit: 1637

The fusion protein is patentably distinct from the method of making a full length coding sequence because the fusion protein can be used in a materially different process such as in a two-hybrid system.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

- 3. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventor ship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventor ship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).
- 4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Cynthia Wilder whose telephone number is (703) 305-1680. The examiner can normally be reached on Monday through Thursday from 9:30 am to 6:30 pm and on Friday from 9:30 am to 1:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached at (703) 308-1119. The official fax phone number for the Group is (703) 308-4242. The unofficial fax number is (703) 308-8724.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to Group's receptionist at (703) 308-0196.

Application/Control Number: 09/937,112

Page 5

Art Unit: 1637

cbw

May 19, 2003

Cynthia B. Wilder, Ph.D.

Patent Examiner Art Unit 1637

O